All In Biotech

Free tool

FAERS Monitor: Femring

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021367 or its brand name (Femring, Estradiol Acetate). Reports on generic versions are filed under their own applications.

Reports

780

Serious

162

21% of reports

Hospitalization

51

Death reported

3

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective176
  • hot flush126
  • therapeutic product effect decreased101
  • device expulsion61
  • headache51
  • insomnia38
  • night sweats35
  • vaginal haemorrhage35
  • vulvovaginal discomfort35
  • product use in unapproved indication32
  • fatigue31
  • off label use31
  • product dose omission issue30
  • feeling abnormal29
  • nausea28

Reports by year received

View as table
YearReports
20045
200520
200611
200723
20086
200910
20108
20118
20128
201313
20147
201515
201680
201768
201870
201976
202035
202148
202249
202345
202450
202581
202644

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,379 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
vulvovaginal discomfortSignal35215.2155.57,195
therapeutic product effect decreasedSignal10160.950.85,894
hot flushSignal12645.238.55,407
night sweatsSignal3529.321.2930
device expulsionSignal6125.419.91,408
vaginal haemorrhageSignal3521.815.7673
insomniaSignal383.82.878
drug ineffectiveSignal1763.63.2350
product use in unapproved indicationSignal323.52.555
feeling abnormalSignal293.32.344
product dose omission issueSignal302.81.932
headacheSignal512.21.733
fatigue311.10.80
off label use311.00.70
nausea281.00.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.